Study identifier:D961HL00001
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
An 8-week, open label, multicentre study to assess the efficacy of esomeprazole 40 mg once daily in subjects with continuing symptoms of heartburn following treatment with a previous rabeprazole.
Heartburn
Phase 4
No
esomeprazole 40 mg
All
101
Interventional
20 Years +
Allocation: N/A
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 Jun 2012 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
Quintiles East Asia Pte. Ltd.
No locations available
Arms | Assigned Interventions |
---|---|
Other: 1 One arm: esomeprazole 40 mg | Drug: esomeprazole 40 mg esomeprazole 40 mg once daily, 8 weeks Other Name: No comparator |